Autopsy report · NCT00249899

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 4 months before it stopped.
649 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Takeda
Sponsor type: Industry
Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy; Stable statin therapy
Participants: 649
Sites: 23
Countries: Canada, South Africa, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.